Diaphragmatic Speckle Tracking During Spontaneous Breathing Trial
DIAST
DIAPHRAGMATIC SPECKLE TRACKING DURING SPONTANEOUS BREATHING TRIAL
1 other identifier
observational
60
1 country
1
Brief Summary
Currently, measurement of transdiaphragmatic pressure (Pdi) using oesophageal and gastric balloons is the gold standard for the assessment of diaphragmatic effort. This technique is relatively invasive and its interpretation may be complex. The diaphragmatic longitudinal strain (LSdi) and strain rate (LSRdi) might provide additional information in the assessment of diaphragmatic effort and movement during SBT, allowing early detection of diaphragmatic dysfunction. Patients will be monitored during a 30-120 minutes SBT consisting of no assistance on the ventilator using CPAP with a pressure level of 0 cmH2O. Parameters to evaluate diaphragm function will include diaphragmatic strain (LSdi and LSRdi), diaphragmatic thickening fraction (TFdi), and airway occlusion pressure (ΔP0.1 and ΔPocc). These parameters will be measured immediately before ('baseline') the SBT, as well as 2 minutes ('early' assessment), 15 ('intermediate' assessment) and 30 minutes ('late' assessment) after the beginning of the SBT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 12, 2023
CompletedFirst Submitted
Initial submission to the registry
July 18, 2023
CompletedFirst Posted
Study publicly available on registry
August 24, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedAugust 24, 2023
July 1, 2023
2 years
July 18, 2023
August 22, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
changes of diaphragmatic longitudinal strain between baseline and during Spontaneous breathing trial
diaphragmatic longitudinal strain is LSdi Spontaneous breathing trial is SBT
7 days
changes of diaphragmatic longitudinal strain strain rate between baseline and during Spontaneous breathing trial
diaphragmatic longitudinal strain strain rate is LSRdi Spontaneous breathing trial is SBT
7 days
Study Arms (1)
adult patients undergoing mechanical ventilation
Eligibility Criteria
Consecutive adult patients (≥18 years old) undergoing mechanical ventilation for at least 24h (regardless of the reason of intubation) and fulfilling criteria for an SBT will be included in the study. Briefly, to be eligible for an SBT, patients will have to (i) be able to trigger ventilator breaths with a reasonable level of assistance, (ii) lack of severe impairment in gas exchange, and (iii) not require significant hemodynamic support. Patients will be recruited by the study coordinator following completion of informed consent from the patient or legally authorized substitute decision maker.
You may qualify if:
- Consecutive adult patients (≥18 years old) undergoing mechanical ventilation for at least 24h (regardless of the reason of intubation)
- patients fulfilling criteria for an SBT
- patients will have to be able to trigger ventilator breaths with a reasonable level of assistance,
- patients with lack of severe impairment in gas exchange,
- patients that not require significant hemodynamic support.
- Patients will be recruited by the study coordinator following completion of informed consent from the patient or legally authorized substitute decision maker.
You may not qualify if:
- Use of pressure support during the SBT.
- Severe hemodynamic instability (\>30% increase in vasopressors in the last 6 hours or norepinephrine \> 0.5 µg/kg/min).
- Severe or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD criteria (stage III: FEV1 30-50% predicted; stage IV: FEV1 \< 30% predicted).
- Known or suspected severe or progressive neuromuscular disorder likely to result in prolonged or chronic ventilator dependence
- Clinical judgement of the attending physician.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Amiens
Amiens, 80480, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 18, 2023
First Posted
August 24, 2023
Study Start
June 12, 2023
Primary Completion
June 1, 2025
Study Completion
June 1, 2025
Last Updated
August 24, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share